Treatment of Type I Cryoglobulinemia with IgM Monoclonal Gammopathy of Undetermined Significance (MGUS)
Clinical scenario
IgM MGUS
This protocol applies to patients with Type I cryoglobulinemia in the setting of IgM monoclonal gammopathy of undetermined significance (MGUS) — a specific sub-population where the immunoglobulin subtype of the underlying gammopathy directly informs the treatment selection.
Treatment approach
Because IgM MGUS reflects lymphoplasmacytic proliferation rather than plasma cell expansion, the preferred therapeutic strategy differs from the approach used for IgG MGUS. The regimen includes a targeted therapy and a specific management precaution related to temperature exposure. The full structured protocol — including dosing, scheduling, and monitoring criteria — is available below.
References
DOI: 10.1016/j.jbspin.2019.01.016
- IgG MGUS, which indicates plasma cell proliferation, is treated with those myeloma drugs that target the plasma cells, whereas rituximab is generally preferred for IgM MGUS, which indicates lymphoplasmacytic proliferation.
- Exposure to low temperatures exacerbates cryoglobulin formation and should therefore be avoided.